Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan.
Genomic profiling with expert tumor boards identifies actionable mutations in real-world Japanese cancer care, guiding precision treatment.
This Scientific Reports study characterizes the real-world performance and clinical utility of comprehensive genomic profiling (CGP) integrated with a molecular tumor board (MTB) system at a single Japanese oncology center. It provides implementation-level data on genomic match rates, actionability, and patient outcomes in the context of Japan's national CGP reimbursement program.
What the study was
- Study design
- retrospective_cohort
- Population
- Cancer patients undergoing CGP with MTB review (single center, Japan)
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Sci Rep
Why it surfaced
Real-world clinical utility data for CGP+MTB implementation in Japan, providing evidence for systematic genomic medicine practice; relevant to precision oncology implementation science; single-center limitation noted.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.